fbpx Further evidence of cognitive and health benefits extends lifestyle intervention | Progress In Mind

Further evidence of cognitive and health benefits extends lifestyle intervention

The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) showed that lifestyle intervention combining nutrition, exercise, cognitive training and monitoring of  vascular and metabolic risk factors significantly benefits cognition in older adults at risk of dementia.1 At AAT-AD/PD, Miia Kivipelto (Karolinska Institute, Stockholm, Sweden) described how this landmark finding is leading to global collaboration. 

Around a third of late onset dementia is attributable to seven risk factors, including diabetes, hypertension, obesity and physical inactivity.2 Hence there is great opportunity for comprehensive lifestyle intervention to reduce dementia incidence.3

The fact that only 10-30% of people with Alzheimer’s dementia have “pure” Alzheimer’s pathology is also in a way encouraging, since it again suggests the promise of intervention against more modifiable risk factors.4

Lifestyle intervention benefits cognition, overall health, and even the telomere

In addition to the 25% improvement on the primary cognition endpoint, the multidomain intervention in FINGER led to 30% lower risk of functional decline (in Independent Activities of Daily Living) and better health related quality of life than among controls who received standard health advice.5 The risk of developing multiple morbidities and of hospitalization was also reduced.

Perhaps most remarkably, the FINGER intervention reduced the shortening of telomeres among APOE4 carriers. Professor Kivipelto also mentioned preliminary evidence that the intervention was cost-effective.

 

Finnish FINGERS extend worldwide

As testament to the importance of these findings, around thirty countries are now involved in a global collaboration as part of the World-Wide FINGERS network, which aims to extend and generalize the multidomain intervention approach that was pioneered in Finland.

The initiative acknowledges that countries with divergent populations will want to organize their own studies and ask their own questions, but it also recognizes the benefits that flow from a degree of harmonization in the interventions used, the outcomes measured, methods of analysis, and data sharing.

The initiative also supports a biorepository to further the study of biomarkers in CSF and blood, genetics, brain imaging, and the microbiome. 

Future prevention efforts will combine pharmacological and lifestyle approaches

 

Combined lifestyle and pharmacological intervention

The future of prevention, as foreseen by Professor Kivipelto, is one in which risk of dementia -- which we know to be multifactorial in origin -- is tackled through comprehensive intervention. This would be composed of multidomain lifestyle intervention together with a cocktail of disease modifying drugs covering amyloid and tau, neurotransmitter modulators, neuroprotective agents, and those targeting dementia risk factors.

As a modest start towards this goal, the phase 2b proof-of-concept MET-Finger-APOE trial now being planned would involve personalized lifestyle intervention in a high-risk group plus the trial of a drug repurposed from the diabetes arena.

 

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

References

1. Ngandu T, et al. Lancet 2015; Jun 6;385:2255-63

2. Norton S, et al. Lancet Neurol 2014;13:788-94

3. Kivipelto M, et al. Nature Reviews Neurology 2018;14:653–66

4. Boyle PA, et al. Ann Neurol 2018;83:74-83

5. Strandberg TE, et al. Eur Ger Med 2017;8:164-7

You are leaving Progress in Mind
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country